You are here

MANDALMED, INC.

Company Information
Address
665 3RD ST STE 250
SAN FRANCISCO, CA 94107-1953
United States


http://www.mandalmed.com

Information

UEI: NPGNAQVJ3VZ7

# of Employees: 4


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: Yes



Award Charts




Award Listing

  1. Novel Ex Vivo Gene Therapy for Spinal Cord Injury

    Amount: $749,980.00

    DESCRIPTION (provided by applicant): There are approximately 10,000 traumatic spinal cord injuries in the United States each year. The average age of injury is 31 years. The majority (90%) of individu ...

    SBIRPhase II2003Department of Health and Human Services National Institutes of Health
  2. NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY

    Amount: $155,695.00

    DESCRIPTION (provided by applicant): The goal of the Phase I research is to develop ex vivo gene therapy that will achieve long-term, localized delivery of human neurotrophin-3 (hNT-3) i ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  3. Novel Treatment for Breast Cancer: Truncated Galectin-3

    Amount: $236,893.00

    DESCRIPTION (provided by applicant): Despite the available treatments breast cancer ranks second as the cause of death from cancer in women pri ...

    SBIRPhase I2001Department of Health and Human Services National Institutes of Health
  4. N/A

    Amount: $142,130.00

    N/A

    SBIRPhase I2000Department of Health and Human Services National Institutes of Health
  5. GALECTIN 1 FOR MULTIPLE SCLEROSIS

    Amount: $135,801.00

    N/A

    SBIRPhase I1999Department of Health and Human Services
  6. THERAPY OF SPINAL CORD INJURY WITH NEUROTROPHIC FACTORS

    Amount: $125,000.00

    N/A

    STTRPhase I1999Department of Health and Human Services
US Flag An Official Website of the United States Government